Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC
24 mai 2022 20h00 HE
|
Verrica Pharmaceuticals Inc.
Verrica has been advised that PAI (Pre-Approval Inspection) was conducted at Sterling and is not aware of any reported observations related to the PAI of VP-102 operations Review Division had advised...
Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results
09 mai 2022 07h30 HE
|
Verrica Pharmaceuticals Inc.
Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum First patient dosed in Phase 2 trial of LTX-315 in basal cell carcinoma WEST CHESTER, Pa., May 09, 2022 (GLOBE...
Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
07 avr. 2022 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
05 avr. 2022 07h30 HE
|
Verrica Pharmaceuticals Inc.
LTX-315’s novel mechanism of action directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to surgery There are approximately 3-4 million...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results
02 mars 2022 16h05 HE
|
Verrica Pharmaceuticals Inc.
NDA for VP-102 for the treatment of molluscum assigned a PDUFA date of May 24, 2022 Company expects to dose first patient in Phase 2 trial of LTX-315 in basal cell carcinoma in the first quarter of...
Verrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference
24 févr. 2022 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum
15 déc. 2021 16h05 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
29 nov. 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
18 nov. 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022 Non-melanoma skin cancers are the most common form of cancer in the U.S., with over 5 million diagnoses each year WEST...
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results
12 nov. 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility’s identified deficiencies from the FDA Verrica is engaging with the FDA...